Despite the evidence for the benefits of anti-VEGF therapy in clinical trials, a recent real-world observational study in the UK showed that the incidence of new blindness due to nAMD increased from year 1 (5.1%) to year 4 (15.6%) in anti-VEGF-treated eyes [12]. This evidence concerns the gene VEGFA and blindness (disorder).